NICE (UK) terminated appraisal for Alhemo (concizumab) for treating haemophilia A or B in people 12 years and over – NovoNordisk

NICE (UK) is unable to make a recommendation on concizumab (Alhemo) for treating haemophilia A or B in people 12 years and over with factor inhibitors. This is because the company did not provide an evidence submission.

Novo Nordisk considers that there is not enough evidence to provide an evidence submission for this appraisal. Because of the small size of the eligible population, there is a high degree of uncertainty in the observational evidence base that would be used to inform an economic model suitable for decision making.